Incremental net benefit in randomized clinical trials
暂无分享,去创建一个
[1] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] S. Stearns,et al. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.
[3] Morris Meisner,et al. Power and Sample Size in Cost- Effectiveness Analysis , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[4] D Polsky,et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.
[5] A R Willan,et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Bernie J. O'Brien,et al. In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.
[7] A R Willan,et al. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.
[8] P. Wakker,et al. Confidence intervals for cost/effectiveness ratios. , 1995, Health economics.
[9] Anastasios A. Tsiatis,et al. A consistent estimator for the distribution of quality adjusted survival time , 1997 .
[10] Elwood Jm,et al. Examining survival data. , 1979 .
[11] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C E Phelps,et al. On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.
[13] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[14] D. Lin,et al. Linear regression analysis of censored medical costs. , 2000, Biostatistics.
[15] J Mullahy. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation. , 1996, Medical care.
[16] A R Willan,et al. Power function arguments in support of an alternative approach for analyzing management trials. , 1994, Controlled clinical trials.
[17] E. Feuer,et al. Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.
[18] R. Gill. Large Sample Behaviour of the Product-Limit Estimator on the Whole Line , 1983 .
[19] M Johannesson,et al. A Note on Confidence Intervals in Cost-Effectiveness Analysis , 1998, International Journal of Technology Assessment in Health Care.
[20] R. Baltussen,et al. The interpretation of results of economic evaluation: explicating the value of health. , 1997, Health economics.
[21] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[22] Amiram Gafni,et al. When Do the "Dollars" Make Sense? , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.